Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CRL - Charles River Laboratories International, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$207.50
DETAILS
HIGH:
$220.00
LOW:
$185.00
MEDIAN:
$214.00
CONSENSUS:
$207.50
UPSIDE:
29.44%
Stock News
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to colla
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, starting i.
Charles River Laboratories International Inc (CRL) Stock Down 5.2% -- Now Undervalued? GF Score: 79/100
On May 12, 2026, Charles River Laboratories International Inc (CRL) shares fell 5.2%, bringing the current price to $168.46. The stock has experienced a 52-week
Charles River (CRL) Reliance on International Sales: What Investors Need to Know
Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is com.
Charles River Laboratories International Q1 Earnings Call Highlights
Charles River Laboratories International NYSE: CRL reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chief Executive Officer Birgit Girshick.
LH vs. CRL: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?
These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results
Charles River Laboratories International, Inc. (NYSE:CRL) posted upbeat earnings for the first quarter, but lowered its FY2026 forecast on Thursday.
These Analysts Increase Their Forecasts On Charles River After Better-Than-Expected Q1 Results
Charles River Laboratories (NYSE: CRL) beat Q1 earnings estimates but lowered its FY2026 forecast. Analysts maintain positive outlook with raised price targets.
Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript
Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript
Charles River Q1 Review: Near-Term Stability But Long-Term Risks (Downgrade)
Charles River Laboratories is downgraded to 'Sell' as shares have rallied 57% in the past year, outpacing fundamentals. Despite Q1 stabilization, organic revenue declined 1.5% and margins compressed, with near-term growth muted and longer-term AI and regulatory risks looming. CRL maintains 2026 EPS guidance of $10.80–$11.30 but trades at 17.5x forward earnings—still at a discount to its history but not considered cheap.
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down
Charles River beats Q1 earnings and revenue estimates, but margin declines and weak organic growth in key segments send shares lower in pre-market.
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charles River Laboratories (CRL) Surpasses Q1 Earnings and Revenue Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $1.96 per share. This compares to earnings of $2.34 per share a year ago.
Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2026
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced financial results for the fiscal first quarter ended April 4, 2026. “Maintaining the momentum of a record fiscal 2025, CRA continued its strong performance into the first quarter of fiscal 2026 as revenue increased by 10.5% year over year to $201.0 million,” said Paul Maleh, CRA's President and Chief Executive Officer. “This re.
Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share
BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced that its Board of Directors has declared a quarterly cash dividend of $0.57 per common share to be paid on June 12, 2026 to shareholders of record of CRA's common stock as of the close of business on May 26, 2026. The Company expects to continue paying quarterly dividends, the declaration, timing and amounts of which remain sub.
Charles River beats quarterly estimates on steady demand for drug development services
Contract drug developer Charles River Laboratories on Thursday beat Wall Street expectations for first-quarter results, helped by improved demand for its drug discovery and development services.
Charles River Laboratories Announces First-Quarter 2026 Results
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2026 Financial Results.
Charles River (CRL) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Charles River (CRL) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Price Targets
Charles River price target raised to $213 from $200 at Baird
$213.00
(was $175.56)
Eric Coldwell
·
Robert W. Baird
Charles River price target raised to $220 from $200 at Evercore ISI
$220.00
(was $176.32)
Evercore ISI
Charles River price target raised to $192 from $175 at Mizuho
$192.00
(was $181.68)
Mizuho Securities
Charles River price target raised to $220 from $210 at Barclays
$220.00
(was $181.68)
Luke Sergott
·
Barclays
Charles River price target raised to $210 from $200 at Barclays
$210.00
(was $178.34)
Luke Sergott
·
Barclays
Charles River initiated with an Outperform at RBC Capital
$215.00
(was $178.34)
RBC Capital
Charles River price target lowered to $175 from $215 at Mizuho
$175.00
(was $164.24)
Mizuho Securities
Charles River price target lowered to $193 from $231 at Baird
$193.00
(was $158.18)
Eric Coldwell
·
Robert W. Baird
Charles River price target lowered to $200 from $215 at Barclays
$200.00
(was $158.00)
Luke Sergott
·
Barclays
Charles River price target raised to $231 from $224 at Baird
$231.00
(was $221.69)
Robert W. Baird
Charles River price target raised to $260 from $250 at Evercore ISI
$260.00
(was $225.11)
Evercore ISI
Charles River price target raised to $224 from $199 at Baird
$224.00
(was $219.49)
Eric Coldwell
·
Robert W. Baird
Charles River price target raised to $215 from $200 at Mizuho
$215.00
(was $215.51)
Ann Hynes
·
Mizuho Securities
Charles River price target raised to $200 from $174 at Mizuho
$200.00
(was $195.98)
Mizuho Securities
Charles River price target raised to $215 from $210 at Barclays
$215.00
(was $192.97)
Barclays
Morgan Stanley Assumes Charles River Labs (CRL) at Equalweight
$185.00
(was $176.09)
Kallum Titchmarsh
·
Morgan Stanley
Charles River upgraded to Buy from Hold at Argus
$200.00
(was $166.73)
Argus Research
Charles River price target raised to $174 from $155 at Mizuho
$174.00
(was $174.95)
Ann Hynes
·
Mizuho Securities
Charles River price target raised to $200 from $190 at Evercore ISI
$200.00
(was $181.18)
Elizabeth Anderson
·
Evercore ISI
Charles River upgraded to Overweight from Equal Weight at Barclays
$195.00
(was $170.48)
Luke Sergott
·
Barclays